Novo Nordisk, Eurofarma to jointly launch two drug brands for weight loss, diabetes

Companies expect products to hit the Brazilian market in October

Danish pharmaceutical company Novo Nordisk and Brazil’s Eurofarma announced on Wednesday (1) a partnership to launch two new brands of injectable biological semaglutide in Brazil for the treatment of obesity and diabetes. The companies said the medications are expected to reach the market as early as October.

Under the agreement, Eurofarma will be the exclusive distributor responsible for the commercialization and promotion of the two weekly injectable semaglutide brands. One will be Poviztra, indicated for the treatment of obesity and overweight with associated comorbidities. The other, Extensior, will target type 2 diabetes treatment.

“This partnership is a strategic step to ensure our innovation reaches even more people across Brazil,” said Allan Finkel, vice president of Novo Nordisk Latam and Brazil, in a joint statement with Eurofarma.

Eurofarma’s Brazil CEO, Renata Campos, said the company will leverage its sales expertise to expand the products’ reach. “A project that reflects a strong commitment to doctors and patients,” she said in the statement.

*By Michael Esquer — São Paulo

Source: Valor International

https://valorinternational.globo.com/